20 minutes |
Jan 27, 2023
Nivolumab in MGMT methylated GBM
52 minutes |
Jan 13, 2023
IDH mutant gliomas; SNO consensus Review
26 minutes |
Dec 30, 2022
DNA methylation subclass and extent of GBM resection
15 minutes |
Dec 16, 2022
Pre-operative [11C]methionine PET for low-grade glioma
17 minutes |
Dec 2, 2022
The role of T lymphocytes in the glioma pathobiology
39 minutes |
Oct 8, 2022
CDKN2A homozygous deletion in IDH mutant astrocytoma
37 minutes |
Sep 23, 2022
EGFR: the lazarus target in glioblastom
33 minutes |
Sep 9, 2022
Brain metastases; a SNO consensus review: Part 2
27 minutes |
Aug 26, 2022
Brain metastases; a SNO consensus review: Part 1
19 minutes |
Aug 13, 2022
Pediatric IDH mutant gliomas
21 minutes |
Jul 29, 2022
Low-risk meningioma: Outcomes from NRG 0539
24 minutes |
Jul 1, 2022
Selumetinib in children with NF1 and plexiform neurofibroma
23 minutes |
Jun 17, 2022
Targeted therapy for BRAF-mutant pediatric glioma
25 minutes |
May 20, 2022
Early/evolving IDH wild-type glioblastoma
25 minutes |
May 6, 2022
PI3K signaling in IDH mutant gliomas
11 minutes |
Apr 22, 2022
Cell-free DNA from CSF in pediatric, adolescent and young adult patients
18 minutes |
Apr 8, 2022
Molecular determinants of neurocognitive deficits in glioma
22 minutes |
Mar 25, 2022
H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma
28 minutes |
Mar 11, 2022
Clinical trial accrual for women and minorities in neuro-oncology
22 minutes |
Feb 11, 2022
The clinical utility of next generation sequencing for IDHwt glioblastoma